NexGel (NexGel) GF Value : $0.00 (As of Jun. 10, 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexGel GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-06-10), NexGel's share price is $2.12. NexGel's GF Value is $0.00. Therefore, NexGel's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes NexGel is Not Valued.

NexGel (NAS:NXGL) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

NexGel's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	2.12	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexGel GF Value Related Terms

Thank you for viewing the detailed overview of NexGel's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NexGel (NexGel) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047

Website

https://www.nexgel.com

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing.

Executives

Steven Mark Glassman	director	99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein	director	QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Scott Robert Henry	director	34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky	director	850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Yaakov Spinrad	director	3450 OAKTON ST, SKOKIE IL 60076
Drapczuk Adam E Iii	officer: Chief Financial Officer	6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc	10 percent owner	C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
Adam R. Levy	officer: CEO and President	2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
David Ian Johnson	director, officer: Chief Executive Officer	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc.	10 percent owner	100 PINE ST., STE. 500, SAN FRANCISCO CA 94111